<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.01.26.21250506</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Endocrinology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Association Between Hypoglycemic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6366-028X</contrib-id>
<name><surname>Han</surname><given-names>Tiantian</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1930-3936</contrib-id>
<name><surname>Ma</surname><given-names>Shaodi</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3812-3164</contrib-id>
<name><surname>Sun</surname><given-names>Chenyu</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a2">b</xref>
<xref ref-type="corresp" rid="cor1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5239-6877</contrib-id>
<name><surname>Zhang</surname><given-names>Huimei</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3943-7368</contrib-id>
<name><surname>Qu</surname><given-names>Guangbo</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2502-9518</contrib-id>
<name><surname>Chen</surname><given-names>Yue</given-names></name>
<xref ref-type="aff" rid="a3">c</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8223-389X</contrib-id>
<name><surname>Cheng</surname><given-names>Ce</given-names></name>
<degrees>DO</degrees>
<xref ref-type="aff" rid="a4">d</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Eric L.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7504-8274</contrib-id>
<name><surname>Ahmed</surname><given-names>Mubashir Ayaz</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Keun Young</given-names></name>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Manem</surname><given-names>Reveena</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Mengshi</given-names></name>
<xref ref-type="aff" rid="a5">e</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4559-4776</contrib-id>
<name><surname>Guo</surname><given-names>Zhichun</given-names></name>
<xref ref-type="aff" rid="a6">f</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5999-1801</contrib-id>
<name><surname>Yang</surname><given-names>Hongru</given-names></name>
<xref ref-type="aff" rid="a6">f</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1387-4973</contrib-id>
<name><surname>Yan</surname><given-names>Yue</given-names></name>
<xref ref-type="aff" rid="a6">f</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4177-6289</contrib-id>
<name><surname>Zhou</surname><given-names>Qin</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a7">g</xref>
</contrib>
<aff id="a1"><label>a</label><institution>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University</institution>, No. 81 Meishan Road, Hefei 230032, Anhui Province, <country>China</country></aff>
<aff id="a2"><label>b</label><institution>Internal Medicine, AMITA Health Saint Joseph Hospital Chicago</institution>, 2900 N. Lake Shore Drive, Chicago 60657, Illinois, <country>USA</country></aff>
<aff id="a3"><label>c</label><institution>Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University</institution>, No. 81 Meishan Road, Hefei 230032, Anhui Province, <country>P.R. China</country></aff>
<aff id="a4"><label>d</label><institution>The University of Arizona College of Medicine at South Campus</institution>, 2800 E Ajo Way, Tucson 85713, AZ, <country>USA</country></aff>
<aff id="a5"><label>e</label><institution>Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University</institution>, No. 932 Lushan Nan Road, Changsha 410083, Hunan Province, <country>China</country></aff>
<aff id="a6"><label>f</label><institution>Massachusetts college of Pharmacy and Health sciences</institution>, 179 Longwood Ave, Boston, MA 02115, <country>USA</country></aff>
<aff id="a7"><label>g</label><institution>Radiation Oncology, Mayo Clinic</institution>, 200 First Street SW, Rochester, MN, 55905, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label>Corresponding author: Chenyu Sun. Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago 60657, Illinois, USA. Telephone number: (773) 665-3000. Fax number: (828) 372-4658. E-mail: <email>drsunchenyu@yeah.net</email>.</corresp>
<fn id="n1" fn-type="equal"><label>&#x002A;</label><p>Tiantian Han and Shaodi Ma contributed equally to this work and should be considered co-first author</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.01.26.21250506</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>1</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21250506.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>During the current Coronavirus Disease 2019 (COVID-19) pandemic, diabetic patients face disproportionately more. Anti-inflammatory effects of hypoglycemic agents have been reported, and their beneficial or harmful effects in patients with diabetes and COVID-19 remain controversial.</p>
</sec>
<sec>
<title>Purpose</title>
<p>This study was performed to clarify this association.</p>
</sec>
<sec>
<title>Data Sources</title>
<p>Relevant literature was searched on China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, Chinese periodical service platform VIP Database, Sinomed (China Biology Medicine, CBM), MedRxiv, PubMed, ScienceDirect, Web of Science, Ovid Databases (LWW), Springer Link, Wiley Online Library, Oxford Academic, Nature Press Group, Cochrane Library and BMJ Evidence-Based Medicine up to November 14, 2020.</p>
</sec>
<sec>
<title>Study Selection</title>
<p>Only observational studies of hypoglycemic agents vs. drugs or therapy without hypoglycemic agents in adult diabetic patients with COVID-19 were included.</p>
</sec>
<sec>
<title>Data Extraction</title>
<p>Data of death and poor composite outcomes were extracted.</p>
</sec>
<sec>
<title>Data Synthesis</title>
<p>The pooled effects were calculated using the fixed-effects or random-effects models based on heterogeneity assessment.</p>
</sec>
<sec>
<title>Limitation</title>
<p>Most studies were retrospective cohort studies with relative weak capability to verify causality.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Home use of metformin might be beneficial in decreasing mortality in diabetic patients infected with SARS-CoV-2. There is insufficient evidence to conclude that metformin and other hypoglycemic agents are associated with poor composite outcomes. More prospective studies, especially RCTs are needed.</p>
</sec>
<sec>
<title>Registration-PROSPERO</title>
<p>CRD42020221951.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keyword</title>
<kwd>Hypoglycemic Agents</kwd>
<kwd>Metformin</kwd>
<kwd>DPP-4 Inhibitors</kwd>
<kwd>Sulfonylurea</kwd>
<kwd>Glinides</kwd>
<kwd>SGLT-2 Inhibitors</kwd>
<kwd>GLP-1 Receptor Agonists</kwd>
<kwd>&#x03B1;-Glycosidase Inhibitors</kwd>
<kwd>Thiazolidinediones</kwd>
<kwd>COVID-19</kwd>
<kwd>SARS-CoV-2</kwd>
</kwd-group>
<counts>
<page-count count="29"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This study is financially supported by Hunan Provincial Key Laboratory of Clinical Epidemiology (grant number: 2020ZNDXLCL002).</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Registration-PROSPERO: CRD42020221951</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Introduction</title>
<p>During the current Coronavirus Disease 2019 (COVID-19) pandemic, there are a limited number of medications evidenced to be effective in treating COVID-19 patients(<xref rid="c1" ref-type="bibr">1</xref>). Although vaccines have been proved effective(<xref rid="c2" ref-type="bibr">2</xref>) and received emergent use authorization in some countries, their long-term protective effect is uncertain and unable to protect the already infected population(<xref rid="c3" ref-type="bibr">3</xref>-<xref rid="c5" ref-type="bibr">5</xref>). The global number of test-positive cases and deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to increase. Accumulating evidence suggests that the release of a large amount of pro-inflammatory cytokines known as &#x201C;cytokine storm&#x201D; triggered by host immune response to the SARS-CoV-2 correlates directly with poor prognosis of COVID-19(<xref rid="c6" ref-type="bibr">6</xref>). Diabetes mellitus was reported as a major comorbidity, ranking after hypertension and cardiovascular disease(<xref rid="c7" ref-type="bibr">7</xref>). The prospective Dutch COVID-PREDICT cohort showed that the presence of hypertension, dyslipidemia and diabetes led to a stepwise increased risk for short-term mortality in hospitalized COVID-19 patients independent of age and sex(<xref rid="c8" ref-type="bibr">8</xref>), and similar results were reported by China CDC Weekly(<xref rid="c9" ref-type="bibr">9</xref>) and American CDC(<xref rid="c10" ref-type="bibr">10</xref>). A meta-analysis containing a total of 6,452 patients from 30 studies showed that diabetes was associated with increased mortality, severe illness, Acute Respiratory Distress Syndrome (ARDS), and disease progression in patients with COVID-19, and this association might be connected by inflammatory response(<xref rid="c11" ref-type="bibr">11</xref>).</p>
<p>Hypoglycemic agents including metformin, dipeptidyl-peptidase 4 inhibitors (DPP-4i), sulfonylurea, glinides, sodium-glucose co-transporter 2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), &#x03B1;-glycosidase inhibitors and thiazolidinediones (TZDs) have been approved, effective, generally safe, and widely used in treating diabetes(<xref rid="c12" ref-type="bibr">12</xref>, <xref rid="c13" ref-type="bibr">13</xref>). Beyond their antidiabetic role, anti-inflammatory and antiviral effects of hypoglycemic agents have been noticed. Metformin, the most prescribed and first-line drug for diabetes, was evaluated as adjuvant therapy for patients with COVID-19(<xref rid="c14" ref-type="bibr">14</xref>). Five clinical trials have been registered thus far, and previous reports of effects of metformin on clinical prognosis of COVID-19 remain controversial(<xref rid="c15" ref-type="bibr">15</xref>, <xref rid="c16" ref-type="bibr">16</xref>). DPP-4i, another commonly used antidiabetic drug, might not protect people from infection as reported in a large case-control study in which DPP-4i was more prevalent in diabetic patients with confirmed COVID-19 than those without COVID-19, but might still play an important role in protecting COVID-19 patients from organ failure and evolving pneumonia to pulmonary fibrosis(<xref rid="c17" ref-type="bibr">17</xref>). A clinical trial is ongoing in France to assess the efficacy of several repurposed drugs against COVID-19 including repaglinide(<xref rid="c18" ref-type="bibr">18</xref>). A propensity-score-matched cohort study also noted the influence of SGLT-2i on susceptibility to COVID-19 in diabetic patients(<xref rid="c19" ref-type="bibr">19</xref>). Unsolved queries remain about the effects of GLP-1RA, &#x03B1;-glycosidase inhibitors, and TZDs in patients with COVID-19. Thus we conducted this systemic review and meta-analysis to further explore queries about effects of hypoglycemic agents on mortality and poor composite outcomes of COVID-19 in diabetic patients.</p>
</sec>
<sec id="s2">
<label>2.</label>
<title>Methods</title>
<p>A systematic review and meta-analysis was conducted under guidance of Meta-analysis Of Observational Studies in Epidemiology (MOOSE)(<xref rid="c20" ref-type="bibr">20</xref>). The PROSPERO registration number is CRD42020221951.</p>
<sec id="s2a">
<label>2.1</label>
<title>Data Sources and Searches</title>
<p>A systematic literature search was performed on China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, Chinese periodical service platform VIP Database, Sinomed (China Biology Medicine, CBM), MedRxiv, PubMed, ScienceDirect, Web of Science, Ovid Databases (LWW), Springer Link, Wiley Online Library, Oxford Academic, Nature Press Group, Cochrane Library, and BMJ Evidence-Based Medicine up to November 14, 2020. Search terms included hypoglycemic agents, metformin, DPP-4i, sulfonylurea, glinides, SGLT-2i, GLP-1RA, &#x03B1;-glycosidase inhibitors and TZDs and COVID-19. Exact search strategy was shown in Table S1. Duplicate results were removed automatically and manually. We screened the remaining articles by reading the title and abstract according to the inclusion and exclusion criteria. And disagreements were solved by discussion. Residual articles were assessed by full text.</p>
</sec>
<sec id="s2b">
<label>2.2</label>
<title>Study Selection</title>
<p>Included studies needed to meet the following criteria: <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline1.gif"/></alternatives></inline-formula>observational study including cohort study, case control study and case series; <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline2.gif"/></alternatives></inline-formula>patients were older than 18 years of age and diagnosed with both diabetes and COVID-19; <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline3.gif"/></alternatives></inline-formula>home use or in-hospital use of specific hypoglycemic agents (including metformin, DPP-4i, sulfonylurea, glinides, SGLT-2i, GLP-1RA, &#x03B1;-glycosidase inhibitors and TZDs) vs. drugs or therapy except specific hypoglycemic agents; <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline4.gif"/></alternatives></inline-formula> clinically validated definition of death, poor composite outcomes including intubation ventilation, Acute Respiratory Distress Syndrome (ARDS), Disseminated intravascular coagulation (DIC), intensive care unit (ICU) admission, disease progression or other adverse outcomes. The following articles were excluded: <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline5.gif"/></alternatives></inline-formula> repeated research; <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline6.gif"/></alternatives></inline-formula> effective data is not applicable; <inline-formula><alternatives><inline-graphic xlink:href="21250506v1_inline7.gif"/></alternatives></inline-formula>could not obtain full text.</p>
</sec>
<sec id="s2c">
<label>2.3</label>
<title>Data Extraction and Quality Assessment</title>
<p>Before collecting data, quality assessment was performed by using Newcastle-Ottawa Quality Assessment Scale(<xref rid="c21" ref-type="bibr">21</xref>). We developed a standardized extraction form to collect the following data: first author&#x2019;s name, year, study date, study geographical region, study design, sample size, male (percentage), groups, death number or unadjusted OR of mortality, adjusted OR/HR of mortality, adjustment factors, poor composite outcomes, data source, home/in-hospital use drugs and NOS stars. Hazard ratios (HRs) were broadly equivalent to risk ratios (RRs) when the risk is not constant with respect to time and RRs were transformed to ORs before merging(<xref rid="c22" ref-type="bibr">22</xref>, <xref rid="c23" ref-type="bibr">23</xref>). Data was extracted and checked. Disagreements were resolved by discussion.</p>
<p>The outcomes of interest were clinically validated definition of death, poor composite outcomes comprised of intubation ventilation, Acute Respiratory Distress Syndrome (ARDS), Disseminated intravascular coagulation (DIC), intensive care unit (ICU) admission, disease progression or other adverse outcomes. We contacted one author for further information that was not presented in detail in one of the published studies.</p>
</sec>
<sec id="s2d">
<label>2.4</label>
<title>Data Synthesis and Analysis</title>
<p>Review Manager 5.3 (Cochrane Collaboration) and Stata 14.0 (Stata, version 14; Stata Corp, College Station, TX, USA) were used for meta-analysis. The effect estimate was reported as pooled odd ratios (ORs) along with its 95&#x0025; confidence intervals (95&#x0025; CIs) by generic inverse variance. To reflect the variation in treatment effects over different settings and the expected effect in future patients, the prediction intervals (PIs) were reported as a supplement to CIs(<xref rid="c24" ref-type="bibr">24</xref>). Pooled ORs, CIs and PIs of mortality, and poor composite outcomes were calculated. Two-tailed P&#x2264;0.05 was considered statistically significant. Q test and I<sup>2</sup> statistic was performed to judge heterogeneity. I<sup>2</sup> &#x003C; 50&#x0025; and P&#x003E;0.1 indicated low statistical heterogeneity, and a fixed effects model would be used; I<sup>2</sup> &#x2265; 50&#x0025; and P&#x003C;0.1 indicated exact heterogeneity, and a random effects model would be used. 95&#x0025; CI of I<sup>2</sup> was reported for further heterogeneity assessment. Funnel plot and Egger&#x2019;s test was done to investigate for publication bias. Sensitivity analysis was performed to explore the source of heterogeneity and determine subsequent analysis. If applicable, subgroup analysis was performed between adjusted or unadjusted ORs, different regions, home or in-hospital use of hypoglycemic agents, drug vs. non-drug in patients with type 2 diabetes only, respectively.</p>
</sec>
</sec>
<sec id="s3">
<label>3.</label>
<title>Results</title>
<sec id="s3a">
<label>3.1</label>
<title>Study selection and characteristics</title>
<p>A total of 925 records were identified through database searching, and 681 records remained after duplicates were removed. After screening the titles and abstracts, 47 records remained and were evaluated by full text. Afterwards, 31 records were excluded for the following reasons: 7 articles were unrelated; 12 articles related to mechanism; 8 articles had no clear comparable groups; 3 articles had no related outcomes; 2 articles were repetitive. Finally, the remaining 16 studies were included for qualitative synthesis, and 14 studies with 13,371 patients were included in quantitative synthesis (meta-analysis). The flow chart is shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Flow diagram of study selection processes</title></caption>
<graphic xlink:href="21250506v1_fig1.tif"/>
</fig>
<p>16 studies were included in qualitative synthesis. Among these, 12 studies related to metformin(<xref rid="c15" ref-type="bibr">15</xref>, <xref rid="c16" ref-type="bibr">16</xref>, <xref rid="c25" ref-type="bibr">25</xref>-<xref rid="c35" ref-type="bibr">35</xref>), 6 studies related to DPP-4i(<xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c28" ref-type="bibr">28</xref>, <xref rid="c33" ref-type="bibr">33</xref>, <xref rid="c35" ref-type="bibr">35</xref>-<xref rid="c38" ref-type="bibr">38</xref>), 3 studies related to sulfonylurea or glinides(<xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c28" ref-type="bibr">28</xref>, <xref rid="c33" ref-type="bibr">33</xref>, <xref rid="c35" ref-type="bibr">35</xref>), 2 studies related to SGLT-2i(<xref rid="c33" ref-type="bibr">33</xref>, <xref rid="c35" ref-type="bibr">35</xref>) and 1 study related to GLP-1RA(<xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c28" ref-type="bibr">28</xref>). Some of these studies included multiple outcomes to different medications. 14 studies were included for quantitative synthesis, among which, 11 studies investigated metformin, and 5 studies investigated DPP-4i. All included studies were assessed with &#x2265;6 stars by NOS. All studies included in quantitative synthesis were cohort studies, and most were electronic medical records collected by clinicians with high authenticity and credibility. Details are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>The main characteristics of studies included in the meta-analysis</p></caption>
<graphic xlink:href="21250506v1_tbl1.tif"/>
<graphic xlink:href="21250506v1_tbl1a.tif"/>
<graphic xlink:href="21250506v1_tbl1b.tif"/>
<graphic xlink:href="21250506v1_tbl1c.tif"/>
</table-wrap>
</sec>
<sec id="s3b">
<label>3.2</label>
<title>Effects of metformin vs. non-metformin on mortality and poor composite outcomes of COVID-19 in diabetic patients</title>
<sec id="s3b1">
<label>3.2.1</label>
<title>Effects of metformin vs. non-metformin on mortality</title>
<p>Meta-analysis of 10 cohort studies investigating mortality risk of COVID-19 for diabetic patients taking metformin showed that metformin was associated with a statistically significant reduced mortality risk (pooled OR=0.56, 95&#x0025; CI, 0.39-0.81, P=0.002, I<sup>2</sup>=77&#x0025;, P&#x003C;0.0001, 95&#x0025; CI of I<sup>2</sup>, 57&#x0025;-83&#x0025;, 95&#x0025; PI, 0.56-4.79) (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Forest plot of the association between metformin and mortality risk of COVID-19 for diabetic patients</title></caption>
<graphic xlink:href="21250506v1_fig2.tif"/>
</fig>
</sec>
<sec id="s3b2">
<label>3.2.2</label>
<title>Subgroup analysis of effect of metformin vs. non-metformin on mortality</title>
<p>Subgroup analysis was performed between adjusted and unadjusted data, home use and in-hospital use of medication, different geographical regions, and metformin vs. non-metformin in patients with type 2 diabetes only to explore potential confounders and expose biases.</p>
<p>After adjustment by age, gender, comorbidities, etc., metformin use was still associated with a statistically significant reduced mortality risk in diabetic patients with COVID-19 (pooled adjusted OR=0.41, 95&#x0025; CI, 0.19-0.91, P=0.03, I<sup>2</sup>=72&#x0025;, P=0.007, 95&#x0025; CI of I<sup>2</sup>, 28&#x0025;-89&#x0025;, 95&#x0025; PI, 0.18-14.74) (Figure S1).</p>
<p>Home use of metformin was associated with a statistically significant reduced death risk (pooled OR=0.60, 95&#x0025; CI, 0.40-0.88, P=0.01, I<sup>2</sup>=81&#x0025;, P&#x003C;0.0001, 95&#x0025; CI of I<sup>2</sup>, 59&#x0025;-91&#x0025;, 95&#x0025; PI, 0.52-5.19), but in-hospital use of metformin did not show such an association (pooled OR=0.44, 95&#x0025; CI, 0.15-1.33, P=0.14, I<sup>2</sup>=74&#x0025;, P=0.01, 95&#x0025; CI of I<sup>2</sup>, 26&#x0025;-91&#x0025;, 95&#x0025; PI, 0.05-55.90) (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Forest plot of the association between metformin and mortality risk of COVID-19 for diabetic patients: home vs. in-hospital use of medication</title></caption>
<graphic xlink:href="21250506v1_fig3.tif"/>
</fig>
<p>The subgroup analysis based on the study locations showed a statistically significant reduced mortality risk of COVID-19 among diabetic patients using metformin in Europe (pooled OR=0.36, 95&#x0025; CI, 0.17-0.73, P=0.005, I<sup>2</sup>=71&#x0025;, P=0.03, 95&#x0025; CI of I<sup>2</sup>, 3&#x0025;-92&#x0025;, 95&#x0025; PI, 0.11-25.63), but not in Asia (pooled OR=0.68, 95&#x0025; CI, 0.33-1.40, P=0.29, I<sup>2</sup>=70&#x0025;, P&#x003C;0.01, 95&#x0025; CI of I<sup>2</sup>, 24&#x0025;-88&#x0025;, 95&#x0025; PI, 0.20-13.48) or North America (pooled OR=0.58, 95&#x0025; CI, 0.25-1.34, P=0.21, I<sup>2</sup>=71&#x0025;, P&#x003C;0.06, 95&#x0025; CI of I<sup>2</sup>, -30&#x0025;-93&#x0025;, 95&#x0025; PI, 0.09-30.69) (Figure S2).</p>
<p>A subgroup analysis of metformin vs. non-metformin in patients with only patients with type 2 diabetes and COVID-19 showed that metformin was not associated with a statistically significant reduced death rate (pooled OR=0.82, 95&#x0025; CI, 0.52-1.29, P=0.39, I<sup>2</sup>=78&#x0025;, P=0.01, 95&#x0025; CI of I<sup>2</sup>, 28&#x0025;-93&#x0025;, 95&#x0025; PI, 0.29-9.35) (Figure S3).</p>
</sec>
<sec id="s3b3">
<label>3.2.3</label>
<title>Publication bias assessment</title>
<p>A funnel plot was drawn to judge the publication bias (Figure S3). Egger&#x2019;s test was performed to quantitatively assess the publication bias (t=-1.78, p=0.112&#x003E;0.05). The results showed no publication bias (Figure S5).</p>
</sec>
<sec id="s3b4">
<label>3.2.4</label>
<title>Sensitivity analysis</title>
<p>We detected significant heterogeneity in analysis of the association between metformin and mortality risk of COVID-19 for diabetic patients (Q test, P&#x003C;0.0001, I<sup>2</sup>=77&#x0025;, 95&#x0025; CI of I<sup>2</sup>, 57&#x0025;-87&#x0025;). To identify the influence of individual studies on combined effects, sensitivity analysis was performed by excluding each original study. The fluctuation of the pooled ORs was found to be between 0.30 and 0.91, with lower limit and upper limit of 95&#x0025; CI constantly less than 1, and P-value constantly less than 0.05, suggesting the stability of this meta-analysis. (Figure S6).</p>
</sec>
<sec id="s3b5">
<label>3.2.5</label>
<title>Effects of metformin vs. non-metformin on poor composite outcomes</title>
<p>Considering different studies reported different outcomes(<xref rid="c15" ref-type="bibr">15</xref>) (<xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c28" ref-type="bibr">28</xref>) (<xref rid="c29" ref-type="bibr">29</xref>) (<xref rid="c31" ref-type="bibr">31</xref>) (<xref rid="c32" ref-type="bibr">32</xref>) (<xref rid="c33" ref-type="bibr">33</xref>) (Table S2), we defined poor composite outcomes to include intubation ventilation, ARDS, DIC, ICU admission, disease progression, and other adverse outcomes (<xref rid="c31" ref-type="bibr">31</xref>, <xref rid="c32" ref-type="bibr">32</xref>). Studies reporting any of these outcomes were included in combined analysis. No statistical significance was found between metformin and poor composite outcomes (pooled OR=0.93, 95&#x0025; CI, 0.79-1.11, P=0.44, I<sup>2</sup>=21&#x0025;, P=0.27) (Figure S7)</p>
</sec>
</sec>
<sec id="s3c">
<label>3.3</label>
<title>Effects of DPP-4i vs. non-DPP-4i on mortality and poor composite outcomes of COVID-19 in diabetic patients</title>
<p>DPP-4i were associated with statistically non-significant reduced risk of mortality (pooled OR=0.63, 95&#x0025; CI, 0.26-1.56, P=0.32, I<sup>2</sup>=77&#x0025;, P=0.005, 95&#x0025; CI of I<sup>2</sup>, 37&#x0025;-92&#x0025;, 95&#x0025; PI, 0.10-27.19) (Figure S8) and poor composite outcomes of COVID-19 in diabetic patients (pooled OR=0.96, 95&#x0025; CI, 0.74-1.26, P=0.78, I<sup>2</sup>=39&#x0025;, P=0.17) (Figure S9).</p>
</sec>
<sec id="s3d">
<label>3.4</label>
<title>Effects of other hypoglycemic agents on prognosis of COVID-19 in diabetic patients</title>
<p>Qualitative analysis was conducted to evaluate other hypoglycemic agents including sulfonylurea, glinides, SGLT-2i, GLP-1RA, &#x03B1;-glycosidase inhibitors and TZDs. Quantitative analysis was not performed due to insufficient data. Three studies investigated sulfonylurea&#x2019;s effects on death. One study investigated the combined use of sulfonylurea and glinides, and found no statistically significant effect on death or tracheal intubation(<xref rid="c27" ref-type="bibr">27</xref>). In addition, no statistically significant result of sulfonylurea&#x2019;s effect on death or severe disease was found in another study(<xref rid="c33" ref-type="bibr">33</xref>), and the last was a case-series study without reporting group outcomes(<xref rid="c35" ref-type="bibr">35</xref>). Eight patients in Kim&#x2019;s study and one patient in Xu&#x2019;s study received SGLT-2i, with the former reporting no statistically significant effect on death or severe disease(<xref rid="c33" ref-type="bibr">33</xref>) and the later didn&#x2019;t report result(<xref rid="c35" ref-type="bibr">35</xref>). The results may have been limited by the small sample size. Cariou&#x2019;s study also included patients who take GLP-1RA; however, no statistically significant effect on death or tracheal intubation was found. We did not find original studies related to &#x03B1;-glycosidase inhibitors or TZDs.</p>
</sec>
</sec>
<sec id="s4">
<label>4.</label>
<title>Discussion</title>
<p>As reported in a retrospective cohort of hospitalized patients in the UK, long-term antidiabetic medications reduced COVID-19 mortality in diabetic patients(<xref rid="c25" ref-type="bibr">25</xref>), which was a very encouraging finding, especially as diabetic patients are particularly susceptible to cumulative organ injury by SARS-CoV-2 because of already compromised pulmonary, cardiac and renal functions. Therefore, furthering our understanding of antidiabetic medications can yield a practical and effective approach in dramatically improving outcomes in this vulnerable population disproportionately affected by COVID-19.</p>
<p>The result of our meta-analysis showed that metformin was associated with a statistically significant reduced mortality for diabetic patients with COVID-19, both before and after adjusting for other factors. This was consistent with several previous small-scale meta-analyses(<xref rid="c39" ref-type="bibr">39</xref>, <xref rid="c40" ref-type="bibr">40</xref>). Home use of metformin was more effective compared to in-hospital use, which was shown in previous analyses(<xref rid="c41" ref-type="bibr">41</xref>). This might be explained by side effects, e.g. an increased risk for metabolic acidosis(<xref rid="c15" ref-type="bibr">15</xref>), induced by metformin(<xref rid="c42" ref-type="bibr">42</xref>) in hospitalized patients. In patients with organ function compromised by COVID-19, the benefits of metformin were likely to be overshadowed by its side effects(<xref rid="c15" ref-type="bibr">15</xref>, <xref rid="c43" ref-type="bibr">43</xref>). As a result, metformin was discontinued and switched to insulin for inpatients in many countries. Benefits of metformin on mortality were more obvious in Europe compared to Asia or North America according to our analysis, although the benefits of metformin were still evident in the United States. For example, a large retrospective review from UnitedHealth Group&#x2019;s Clinical Discovery Database in the USA reported that home use of metformin was significantly associated with reduced mortality in female inpatients with COVID-19, and reduction of TNF-&#x03B1; might underly the mechanistic pathway(<xref rid="c26" ref-type="bibr">26</xref>). In addition, confounders such as race, gender, and disease severity require further study. Metformin had no beneficial effects on poor composite outcomes including tracheal intubation, ARDS, DIC, ICU admission, and disease progression, indicating that metformin might be more effective in reducing mortality risk in severe or critical illness, while not preventing disease progression to severe or critical illness. Current discussions on metformin&#x2019;s role in reducing COVID-19 mortality involves several different mechanisms. One possible mechanism is that metformin inhibits cytokine storm by suppressing interleukin-6 (IL-6) signaling, preventing the process of lung fibrosis and suppressing endocytosis, thereby elevating angiotensin converting enzyme 2 (ACE2) expression(<xref rid="c44" ref-type="bibr">44</xref>). Increased ACE2 offers cardiopulmonary benefits in patients with COVID-19 by activating AMP-activated protein kinase (AMPK), which is involved in phosphorylating key molecules regulating metabolism and cardiovascular health(<xref rid="c45" ref-type="bibr">45</xref>). Activated AMPK phosphorylates ACE2, thereby changing conformation and function of ACE2 and resulting in decreased integration with the SARS-CoV-2 receptor and binding domain due to steric hindrance(<xref rid="c46" ref-type="bibr">46</xref>). The mortality benefits may also be explained by metformin&#x2019;s effect on cellular pH, which needs to be acidic for optimal viral membrane fusion of SARS-CoV-2. By increasing cellular pH, metformin subsequently interferes with the endocytic cycle to inhibit viral infection by acting on the eNHEs and/or the V-ATPase(<xref rid="c14" ref-type="bibr">14</xref>). Reducing production of proinflammatory cytokines by macrophages and formation of neutrophil extracellular traps (NETs) might play a role as well(<xref rid="c43" ref-type="bibr">43</xref>). Although current evidence supports metformin use, further studies are needed to understand its mechanistic link to mortality benefits.</p>
<p>Use of DPP-4i for diabetic patients is not associated with statistically non-significant reduced death or poor composite outcomes of COVID-19 according to our analysis. Previous studies comparing the prevalence of DPP-4i use between diabetic patients with or without COVID-19 showed that DPP-4i use was more prevalent in COVID-19 patients(<xref rid="c47" ref-type="bibr">47</xref>), implying that DPP-4i might not prevent people from contracting SARS-CoV-2(<xref rid="c48" ref-type="bibr">48</xref>). However, some opinions indicated that diabetic patients with COVID-19 could benefit from DPP-4i not only by controlling blood glucose, but also improving long-term prognosis of COVID-19 caused by pulmonary fibrosis, heart and kidney injury via blocking the tissue remodeling function of activating myofibroblasts and migrating fibroblasts, suppressing inflammatory sign and proliferating vascular smooth muscle cells to avoid adverse outcomes(<xref rid="c17" ref-type="bibr">17</xref>). As DPP-4 is hypothesized to be a binding partner for corona-like viruses to enter host immune cells, DPP-4i also exerts influence on prohibiting invasion of SARS-CoV-2 into cells(<xref rid="c49" ref-type="bibr">49</xref>). However, concentration of circulating soluble DPP-4 serum in patients suffering from severe COVID-19 was significantly lower compared to that in healthy human subjects(<xref rid="c50" ref-type="bibr">50</xref>), which contradicts the protective effects of DPP-4i. Sitagliptin, a DPP-4i drug, was thought to have anti-inflammatory effects on diabetic patients via the NF-kappa-B signaling pathway (<xref rid="c51" ref-type="bibr">51</xref>). This hypothesis needs to be verified by more studies.</p>
<p>Existing studies of other hypoglycemic agents, including sulfonylurea, glinides, SGLT-2i, GLP-1RA, &#x03B1;-glycosidase inhibitors, and TZDs, were insufficient for quantitative analysis. Apart from existing clinical studies, an <italic>in vitro</italic> experiment found that E protein, a potential ion channel on SARS-CoV-2, could be inhibited by Gliclazide (a type of sulfonylurea)(<xref rid="c52" ref-type="bibr">52</xref>). A propensity-score-matched cohort study showed that SGLT-2i did not decrease susceptibility compared to DPP-4i(<xref rid="c19" ref-type="bibr">19</xref>). Dapagliflozin, a type of SGLT-2i, was assumed to reduce the viral load by lowering of cytosolic pH(<xref rid="c53" ref-type="bibr">53</xref>). GLP-1RA was considered for treating asymptomatic and non-critically ill COVID-19 patients due to its anti-inflammatory effects(<xref rid="c54" ref-type="bibr">54</xref>) and this effect might be related with ACE2 as well. Pioglitazone, a common type of TZDs, was recommended to treat COVID-19 patients for its potential to improve liver injuries(<xref rid="c55" ref-type="bibr">55</xref>) and block macrophage activation by uptake of oxidized LDL to reduce the progression of atherosclerosis, which results in less risk of developing into severe illness of COVID-19(<xref rid="c56" ref-type="bibr">56</xref>).</p>
<p>Heterogeneity existed in analysis of effects of metformin on mortality risk and effects of DPP-4i on mortality risk and poor composite outcomes. Even after subgroup analysis of adjusted and unadjusted data, home use and in-hospital use of medication, different geographic regions, and drug vs. non-drug in patients with type 2 diabetes only, heterogeneity was not eliminated or significantly reduced. Sensitivity analysis did not identify any specific original study that led to unstable results, which might be explained by the discrepancy of included studies themselves. Gender ratio and average age accounted for a portion of unstable results as female and young patients(<xref rid="c30" ref-type="bibr">30</xref>, <xref rid="c34" ref-type="bibr">34</xref>) reportedly have a better prognosis. Elements including duration of medication (from &#x003C;21 day(<xref rid="c25" ref-type="bibr">25</xref>) to &#x003E;6 months), dose, common drugs in exposure and control groups(<xref rid="c29" ref-type="bibr">29</xref>), long-term blood glucose control (HbA1c)(<xref rid="c34" ref-type="bibr">34</xref>, <xref rid="c57" ref-type="bibr">57</xref>), BMI(<xref rid="c26" ref-type="bibr">26</xref>) and comorbidities(<xref rid="c58" ref-type="bibr">58</xref>) varied in different studies and were likely related to heterogeneity. We also calculated the prediction interval (PI) to reflect the variation in treatment effects over different settings, predict the expected effect on future patients as a supplement to CI(<xref rid="c24" ref-type="bibr">24</xref>) and 95&#x0025; CI of I<sup>2</sup> described the proportion of total variation in study estimates that is due to heterogeneity (<xref rid="c59" ref-type="bibr">59</xref>). Results showed unstable predictive effects and heterogeneity which urges some caution about the findings.</p>
<p>In addition, there are several other potential limitations. Firstly, meta-analyses are inherently subject to design biases and variations of included original studies with discrepancies in methods and patient characteristics; despite this, statistically significant results were achieved by inclusion of large-sample studies and more original studies, as well as various dimensions and parameters of analysis to expose confounding variables and narrow this discrepancy. Although most studies contained in our analysis were electronic medical records collected by clinicians with high authenticity and credibility, most studies were retrospective cohort studies with relative weak capability to verify causality. As participants of Bramante&#x2019; study included both diabetic patients and patients with obesity(<xref rid="c26" ref-type="bibr">26</xref>), confounding factors such as obesity may have influenced the result. Participants in Cariou&#x2019;s study were observed for only 7 days to draw conclusions, while longer follow-up period was preferred. We contacted the author for raw data, but as there was no response, the HR was directly merged with other studies&#x2019; OR which may marginally affect the pooled OR, but would not change the final conclusion.</p>
</sec>
<sec id="s5">
<label>5.</label>
<title>Conclusion</title>
<p>Metformin is associated with reduced mortality of COVID-19 in diabetic patients, and no evidence of decreasing poor composite outcomes (intubation ventilation, ARDS, ICU admission, disease progression, and other adverse outcomes) has yet been found. Long-term home use of metformin is strongly supported because of its anti-inflammatory and antiviral effects. DPP-4i is not associated with a reduced risk of death or poor composite outcomes in diabetic patients with COVID-19. Current evidence is insufficient to draw a solid conclusion regarding the effects of sulfonylurea, glinides, SGLT-2i, GLP-1RA, &#x03B1;-glycosidase inhibitors or TZD on clinical outcomes of COVID-19 in diabetic patients. More prospective research studies, especially RCTs, are needed to verify and explore the effects of hypoglycemic agents on COVID-19 in diabetic patients.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Table S1, Table S2</label>
<media xlink:href="supplements/250506_file05.pdf" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>The raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.</p>
</sec>
<ack>
<label>6.</label>
<title>Acknowledgments</title>
<p>Author contributions: Tiantian Han and Dr. Chenyu Sun designed research; Tiantian Han, Shaodi Ma, Huimei Zhang and Guangbo Qu conducted literature search and data extraction; Tiantian Han, Shaodi Ma, Huimei Zhang, Guangbo Qu and Dr. Chenyu Sun analyzed data; Tiantian Han and Dr. Chenyu Sun wrote the paper. Dr. Chenyu Sun, Yue Chen, Dr. Ce Cheng, Dr. Mubashir Ayaz Ahmed, Keun Young Kim, Dr. Eric Chen, Dr. Reveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan; Qin Zhou revised the paper. All authors read and approved the final manuscript. We appreciate all authors for their contributions, and support from AMITA Health Saint Joseph Hospital Chicago and Anhui Medical University.</p>
<p>Tiantian Han and Shaodi Ma had primary responsibility for final content. Dr. Chenyu Sun is the corresponding author. This study is financially supported by Hunan Provincial Key Laboratory of Clinical Epidemiology (grant number: 2020ZNDXLCL002). No conflict of interest.</p>
</ack>
<ref-list>
<title>Reference</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Jean</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hsueh</surname> <given-names>P.</given-names></string-name> <article-title>Treatment options for COVID-19: The reality and challenges</article-title>. <source>Journal of microbiology, immunology and infection</source> <year>2020</year>; <volume>53</volume>(<issue>3</issue>):<fpage>436</fpage>&#x2013;<lpage>443</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Polack</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kitchin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Absalon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gurtman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lockhart</surname> <given-names>S</given-names></string-name>, <string-name><surname>Perez</surname> <given-names>JL</given-names></string-name>, <string-name><surname>P&#x00E9;rez Marc</surname> <given-names>G</given-names></string-name>, <string-name><surname>Moreira</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Zerbini</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bailey</surname> <given-names>R</given-names></string-name>, <string-name><surname>Swanson</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Roychoudhury</surname> <given-names>S</given-names></string-name>, <string-name><surname>Koury</surname> <given-names>K</given-names></string-name>, <string-name><surname>Li</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kalina</surname> <given-names>WV</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>D</given-names></string-name>, <string-name><surname>Frenck</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Hammitt</surname> <given-names>LL</given-names></string-name>, <string-name><surname>T&#x00FC;reci</surname> <given-names>&#x00D6;</given-names></string-name>, <string-name><surname>Nell</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sc haefer</surname> <given-names>A</given-names></string-name>, <string-name><surname>&#x00DC;nal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tresnan</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Mather</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dormitzer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>&#x015E;ahin</surname> <given-names>U</given-names></string-name>, <string-name><surname>Jansen</surname> <given-names>KU</given-names></string-name>, <string-name><surname>Gruber</surname> <given-names>WC</given-names></string-name>. <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>NEW ENGL J MED</source> <year>2020</year>; <volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>&#x2013; <lpage>2615</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Doshi</surname> <given-names>P.</given-names></string-name> <article-title>Will covid-19 vaccines save lives? Current trials aren&#x2019;t designed to tell us</article-title>. <source>BMJ</source> <year>2020</year>; <volume>371</volume>:<fpage>m4037</fpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Awadasseid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tanaka</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>W.</given-names></string-name> <article-title>Current advances in the development of SARS-CoV-2 vaccines</article-title>. <source>INT J BIOL SCI</source> <year>2021</year>; <volume>17</volume>(<issue>1</issue>):<fpage>8</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Xiang</surname> <given-names>T</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>N</given-names></string-name>, <string-name><surname>Yu Y</surname>, <given-names>Al.</given-names></string-name> <article-title>E. Expert consensus on emergency vaccination of novel coronavirus vaccine by staff of medical institutions</article-title>. <source>Chinese Journal of Experimental and Clinical Infectious Diseases</source> <year>2021</year>; <volume>14</volume>(<issue>6</issue>):<fpage>441</fpage>&#x2013;<lpage>446</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Hu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yin</surname> <given-names>L.</given-names></string-name> <article-title>The cytokine storm and COVID-19</article-title>. <source>J MED VIROL</source> <year>2021</year>; <volume>93</volume>(<issue>1</issue>):<fpage>250</fpage>&#x2013;<lpage>256</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Emami</surname> <given-names>A</given-names></string-name>, <string-name><surname>Javanmardi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Pirbonyeh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Akbari</surname> <given-names>A.</given-names></string-name> <article-title>Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis</article-title>. <source>Archives Academic Emergency Medicine</source> <year>2020</year>; <volume>8</volume>(<issue>1</issue>):<fpage>e35</fpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="other"><string-name><surname>Collard</surname> <given-names>D</given-names></string-name>, <string-name><surname>Nurmohamed</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Reeskamp</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Dormans</surname> <given-names>T</given-names></string-name>, <string-name><surname>Moeniralam</surname> <given-names>H</given-names></string-name>, <string-name><surname>Simsek</surname> <given-names>S</given-names></string-name>, <string-name><surname>Douma</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Eerens</surname> <given-names>A</given-names></string-name>, <string-name><surname>Reidinga</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Elbers</surname> <given-names>P</given-names></string-name>, <string-name><surname>Beudel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vogt</surname> <given-names>L</given-names></string-name>, <string-name><surname>Stroes</surname> <given-names>ESG</given-names></string-name>, <string-name><surname>van den Born</surname> <given-names>BH</given-names></string-name>. <article-title>Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study</article-title>. <source>medRxiv</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><collab>The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) &#x2014; China, 2020</collab>. <source>China CDC Weekly</source> <year>2020</year>; <volume>2</volume>(<issue>8</issue>):<fpage>113</fpage>&#x2013;<lpage>122</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="other"><collab>Evidence used to update the list of underlying medical conditions that increase a person&#x2019;s risk of severe illness from COVID-19</collab>.; <year>2020</year>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname> <given-names>I</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Pranata</surname> <given-names>R.</given-names></string-name> <article-title>Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression</article-title>. <source>Diabetes &#x0026; Metabolic Syndrome</source> <year>2020</year>; <volume>14</volume>(<issue>4</issue>):<fpage>395</fpage>&#x2013;<lpage>403</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Society</surname> <given-names>CD</given-names></string-name>. <article-title>Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition)</article-title>. <source>Chinese Journal of Practical Internal Medicine</source> <year>2018</year>; <volume>38</volume>(<issue>04</issue>):<fpage>292</fpage>&#x2013;<lpage>344</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><collab>Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes &#x2014; 2021</collab>. <source>DIABETES CARE</source> <year>2021</year>; <volume>44</volume>(<issue>Supplement 1</issue>):<fpage>S111</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Esam</surname> <given-names>Z.</given-names></string-name> <article-title>A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19</article-title>. <source>DIABETES RES CLIN PR</source> <year>2020</year>; <volume>167</volume>:<fpage>108282</fpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Cheng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lei</surname> <given-names>F</given-names></string-name>, <string-name><surname>Qin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Song</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ye</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>W</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>B</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>X</given-names></string-name>, <string-name><surname>She</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Ji</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H.</given-names></string-name> <article-title>Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes</article-title>. <source>CELL METAB</source> <year>2020</year>; <volume>32</volume>(<issue>4</issue>):<fpage>537</fpage>&#x2013;<lpage>547</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Luo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Xue</surname> <given-names>H</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Li</surname> <given-names>J.</given-names></string-name> <article-title>Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis</article-title>. <source>The American Journal of Tropical Medicine and Hygiene</source> <year>2020</year>; <volume>103</volume>(<issue>1</issue>):<fpage>69</fpage>&#x2013;<lpage>72</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Smelcerovic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kocic</surname> <given-names>G</given-names></string-name>, <string-name><surname>Gajic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tomovic</surname> <given-names>K</given-names></string-name>, <string-name><surname>Djordjevic</surname> <given-names>V</given-names></string-name>, <string-name><surname>Stankovic-Djordjevic</surname> <given-names>D</given-names></string-name>, <string-name><surname>Anderluh</surname> <given-names>M.</given-names></string-name> <article-title>DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19&#x2014; A Therapeutic Approach of Choice in Type 2 Diabetic Patients?</article-title> <source>FRONT PHARMACOL</source> <year>2020</year>; <volume>11</volume>:<fpage>1185</fpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Duvignaud</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lhomme</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pistone</surname> <given-names>T</given-names></string-name>, <string-name><surname>Onaisi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sitta</surname> <given-names>R</given-names></string-name>, <string-name><surname>Journot</surname> <given-names>V</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Peiffer-Smadja</surname> <given-names>N</given-names></string-name>, <string-name><surname>Cr&#x00E9;mer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bouchet</surname> <given-names>S</given-names></string-name>, <string-name><surname>Darnaud</surname> <given-names>T</given-names></string-name>, <string-name><surname>Poitrenaud</surname> <given-names>D</given-names></string-name>, <string-name><surname>Piroth</surname> <given-names>L</given-names></string-name>, <string-name><surname>Binquet</surname> <given-names>C</given-names></string-name>, <string-name><surname>Michel</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Lef&#x00E8;vre</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lebeaux</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lebel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dupouy</surname> <given-names>J</given-names></string-name>, <string-name><surname>Roussillon</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gimbert</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wittkop</surname> <given-names>L</given-names></string-name>, <string-name><surname>Thi&#x00E9;baut</surname> <given-names>R</given-names></string-name>, <string-name><surname>Orne-Gliemann</surname> <given-names>J</given-names></string-name>, <string-name><surname>Joseph</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Richert</surname> <given-names>L</given-names></string-name>, <string-name><surname>Anglaret</surname> <given-names>X</given-names></string-name>, <string-name><surname>Malvy</surname> <given-names>D.</given-names></string-name> <article-title>Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)</article-title>. <source>TRIALS</source> <year>2020</year>; <volume>21</volume>(<issue>1</issue>):<fpage>846</fpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Sainsbury</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gokhale</surname> <given-names>K</given-names></string-name>, <string-name><surname>Acosta-Mena</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dhalla</surname> <given-names>S</given-names></string-name>, <string-name><surname>Byne</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chandan</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Anand</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>J</given-names></string-name>, <string-name><surname>Okoth</surname> <given-names>K</given-names></string-name>, <string-name><surname>Subramanian</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bangash</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Taverner</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hanif</surname> <given-names>W</given-names></string-name>, <string-name><surname>Ghosh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Narendran</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Marshall</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gkoutos</surname> <given-names>G</given-names></string-name>, <string-name><surname>Toulis</surname> <given-names>K</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>N</given-names></string-name>, <string-name><surname>Tahrani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Adderley</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Haroon</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nirantharakumar</surname> <given-names>K.</given-names></string-name> <article-title>Sodium-glucose co- transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study</article-title>. <source>Diabetes, Obesity &#x0026; Metabolism</source> <year>2021</year>; <volume>23</volume>(<issue>1</issue>):<fpage>263</fpage>&#x2013;<lpage>269</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Stroup</surname> <given-names>DF</given-names></string-name>. <article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group</article-title>. <source>JAMA</source> <year>2000</year>; <volume>283</volume>(<issue>15</issue>):<fpage>2008</fpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="other"><string-name><surname>Wells</surname> <given-names>G</given-names></string-name>, <string-name><surname>Shea</surname> <given-names>B</given-names></string-name>, <string-name><surname>O&#x2019;Connell</surname> <given-names>D</given-names></string-name>, <string-name><surname>Peterson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Welch</surname> <given-names>V</given-names></string-name>, <string-name><surname>Losos</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tugwell</surname> <given-names>P.</given-names></string-name> <source>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses</source>. <year>2013</year>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Ronksley</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Brien</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Mukamal</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Ghali</surname> <given-names>WA</given-names></string-name>. <article-title>Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis</article-title>. <source>BMJ</source> <year>2011</year>; <volume>342</volume>:<fpage>d671</fpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Stare</surname> <given-names>J</given-names></string-name>, <string-name><given-names>Maucort-Boulch D. Odds</given-names> <surname>Ratio</surname></string-name>, <string-name><given-names>Hazard</given-names> <surname>Ratio</surname></string-name> and <string-name><given-names>Relative</given-names> <surname>Risk</surname></string-name>. <source>Metodoloski Zvezki</source> <year>2016</year>; <volume>13</volume>(<issue>1</issue>):<fpage>59</fpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>IntHout</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ioannidis</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Rovers</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Goeman</surname> <given-names>JJ</given-names></string-name>. <article-title>Plea for routinely presenting prediction intervals in meta- analysis</article-title>. <source>BMJ OPEN</source> <year>2016</year>; <volume>6</volume>(<issue>7</issue>):<fpage>e10247</fpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="other"><string-name><surname>Abu-Jamous</surname> <given-names>B</given-names></string-name>, <string-name><surname>Anisimovich</surname> <given-names>A</given-names></string-name>, <string-name><surname>Baxter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mackillop L</surname>, <given-names>P</given-names></string-name> <string-name><given-names>M</given-names>, <surname>Vizcaychipi</surname></string-name>, <string-name><surname>McCarthy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>RT</given-names></string-name>. <article-title>Associations of comorbidities and medications with COVID-19 2 outcome: A retrospective analysis of real-world evidence data</article-title>. <source>medRxiv</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="other"><string-name><surname>Bramante</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ingraham</surname> <given-names>N</given-names></string-name>, <string-name><surname>Murray</surname> <given-names>T</given-names></string-name>, <string-name><surname>Marmor</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hoversten</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gronski</surname> <given-names>J</given-names></string-name>, <string-name><surname>McNeil</surname> <given-names>C</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>R</given-names></string-name>, <string-name><surname>Guzman</surname> <given-names>G</given-names></string-name>, <string-name><surname>Abdelwahab</surname> <given-names>N</given-names></string-name>, <string-name><surname>King</surname> <given-names>S</given-names></string-name>, <string-name><surname>Meehan</surname> <given-names>T</given-names></string-name>, <string-name><surname>Benson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pendleton</surname> <given-names>K</given-names></string-name>, <string-name><surname>Vojta</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tignanelli</surname> <given-names>CJ</given-names></string-name>. <article-title>Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19</article-title>. <source>medRxiv</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Cariou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hadjadj</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wargny</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pichelin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Al-Salameh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Allix</surname> <given-names>I</given-names></string-name>, <string-name><surname>Amadou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Arnault</surname> <given-names>G</given-names></string-name>, <string-name><surname>Baudoux</surname> <given-names>F</given-names></string-name>, <string-name><surname>Bauduceau</surname> <given-names>B</given-names></string-name>, <string-name><surname>Borot</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bourgeon-Ghittori</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bourron</surname> <given-names>O</given-names></string-name>, <string-name><surname>Boutoille</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cazenave-Roblot</surname> <given-names>F</given-names></string-name>, <string-name><surname>Chaumeil</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cosson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Coudol</surname> <given-names>S</given-names></string-name>, <string-name><surname>Darmon</surname> <given-names>P</given-names></string-name>, <string-name><surname>Disse</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ducet-Boiffard</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gaborit</surname> <given-names>B</given-names></string-name>, <string-name><surname>Joubert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kerlan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Laviolle</surname> <given-names>B</given-names></string-name>, <string-name><surname>Marchand</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Potier</surname> <given-names>L</given-names></string-name>, <string-name><surname>Prevost</surname> <given-names>G</given-names></string-name>, <string-name><surname>Riveline</surname> <given-names>J</given-names></string-name>, <string-name><surname>Robert</surname> <given-names>R</given-names></string-name>, <string-name><surname>Saulnier</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sultan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Th&#x00E9;baut</surname> <given-names>J</given-names></string-name>, <string-name><surname>Thivolet</surname> <given-names>C</given-names></string-name>, <string-name><surname>Tramunt</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vatier</surname> <given-names>C</given-names></string-name>, <string-name><surname>Roussel</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gautier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gourdy</surname> <given-names>P.</given-names></string-name> <article-title>Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study</article-title>. <source>DIABETOLOGIA</source> <year>2020</year>; <volume>63</volume>(<issue>9</issue>):<fpage>1953</fpage>&#x2013;<lpage>1957</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Cariou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hadjadj</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wargny</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pichelin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Al-Salameh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Allix</surname> <given-names>I</given-names></string-name>, <string-name><surname>Amadou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Arnault</surname> <given-names>G</given-names></string-name>, <string-name><surname>Baudoux</surname> <given-names>F</given-names></string-name>, <string-name><surname>Bauduceau</surname> <given-names>B</given-names></string-name>, <string-name><surname>Borot</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bourgeon-Ghittori</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bourron</surname> <given-names>O</given-names></string-name>, <string-name><surname>Boutoille</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cazenave-Roblot</surname> <given-names>F</given-names></string-name>, <string-name><surname>Chaumeil</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cosson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Coudol</surname> <given-names>S</given-names></string-name>, <string-name><surname>Darmon</surname> <given-names>P</given-names></string-name>, <string-name><surname>Disse</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ducet-Boiffard</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gaborit</surname> <given-names>B</given-names></string-name>, <string-name><surname>Joubert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kerlan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Laviolle</surname> <given-names>B</given-names></string-name>, <string-name><surname>Marchand</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Potier</surname> <given-names>L</given-names></string-name>, <string-name><surname>Prevost</surname> <given-names>G</given-names></string-name>, <string-name><surname>Riveline</surname> <given-names>J</given-names></string-name>, <string-name><surname>Robert</surname> <given-names>R</given-names></string-name>, <string-name><surname>Saulnier</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sultan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Th&#x00E9;baut</surname> <given-names>J</given-names></string-name>, <string-name><surname>Thivolet</surname> <given-names>C</given-names></string-name>, <string-name><surname>Tramunt</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vatier</surname> <given-names>C</given-names></string-name>, <string-name><surname>Roussel</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gautier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gourdy</surname> <given-names>P.</given-names></string-name> <article-title>Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study</article-title>. <source>DIABETOLOGIA</source> <year>2020</year>; <volume>63</volume>(<issue>8</issue>):<fpage>1500</fpage>&#x2013;<lpage>1515</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>A</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>M</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>K.</given-names></string-name> <article-title>Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose- Lowering Medication</article-title>. <source>DIABETES CARE</source> <year>2020</year>; <volume>43</volume>(<issue>7</issue>):<fpage>1399</fpage>&#x2013;<lpage>1407</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="other"><string-name><surname>Crouse</surname> <given-names>A</given-names></string-name>, <string-name><surname>Grimes</surname> <given-names>T</given-names></string-name>, <string-name><surname>Li</surname> <given-names>P</given-names></string-name>, <string-name><surname>Might</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ovalle</surname> <given-names>F</given-names></string-name>, <string-name><surname>Shalev</surname> <given-names>A.</given-names></string-name> <article-title>Metformin Use is Associated with Reduced Mortality in a Diverse Population with Covid-19 and Diabetes</article-title>. <source>medRxiv</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="other"><string-name><surname>Do</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Kang</surname> <given-names>SH</given-names></string-name>. <article-title>Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?</article-title> <source>DIABETES METAB</source> <year>2020</year>:<fpage>S1262</fpage>&#x2013;<lpage>S3636</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Gao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>W</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>H</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>W.</given-names></string-name> <article-title>Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report</article-title>. <source>Clinical and Translational Science</source> <year>2020</year>; <volume>13</volume>(<issue>6</issue>):<fpage>1055</fpage>&#x2013;<lpage>1059</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Jeon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moon</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>NH</given-names></string-name>, <string-name><surname>Han</surname> <given-names>E</given-names></string-name>, <string-name><surname>You</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Hyun</surname> <given-names>M</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Kwon</surname> <given-names>YS</given-names></string-name>, <string-name><surname>Choi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kwon</surname> <given-names>KT</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Jeon</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hong</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kwon</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Jung</surname> <given-names>CY</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>YY</given-names></string-name>, <string-name><surname>Ha</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Hur</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ahn</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Park</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J.</given-names></string-name> <article-title>The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea</article-title>. <source>DIABETES METAB J</source> <year>2020</year>; <volume>44</volume>(<issue>4</issue>):<fpage>602</fpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Shestakova</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Vikulova</surname> <given-names>OK</given-names></string-name>, <string-name><surname>Isakov</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dedov</surname> <given-names>II</given-names></string-name>. <article-title>Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry</article-title>. <source>Problems of Endocrinology</source> <year>2020</year>; <volume>66</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2013;<lpage>46</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Xu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ye</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tesfaye</surname> <given-names>S</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>L.</given-names></string-name> <article-title>The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19</article-title>. <source>J DIABETES</source> <year>2020</year>; <volume>12</volume>(<issue>12</issue>):<fpage>909</fpage>&#x2013;<lpage>918</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Fadini</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Morieri</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Longato</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bonora</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Pinelli</surname> <given-names>S</given-names></string-name>, <string-name><surname>Selmin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Voltan</surname> <given-names>G</given-names></string-name>, <string-name><surname>Falaguasta</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tresso</surname> <given-names>S</given-names></string-name>, <string-name><surname>Costantini</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sparacino</surname> <given-names>G</given-names></string-name>, <string-name><surname>Di Camillo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Tramontan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cattelan</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Vianello</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fioretto</surname> <given-names>P</given-names></string-name>, <string-name><surname>Vettor</surname> <given-names>R</given-names></string-name>, <string-name><surname>Avogaro</surname> <given-names>A.</given-names></string-name> <article-title>Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case- control study</article-title>. <source>Diabetes, Obesity and Metabolism</source> <year>2020</year>; <volume>22</volume>(<issue>10</issue>):<fpage>1946</fpage>&#x2013;<lpage>1950</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="other"><string-name><surname>Rhee</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nam</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kyoung</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>DJ</given-names></string-name>. <article-title>Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19</article-title>. <source>medRxiv</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Solerte SB</surname>, <given-names>D</given-names></string-name> <string-name><surname>Addio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Trevisan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lovati</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rossi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pastore</surname> <given-names>I</given-names></string-name>, <string-name><surname>Dell Acqua</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ippolito</surname> <given-names>E</given-names></string-name>, <string-name><surname>Scaranna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bellante</surname> <given-names>R</given-names></string-name>, <string-name><surname>Galliani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dodesini</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Lepore</surname> <given-names>G</given-names></string-name>, <string-name><surname>Geni</surname> <given-names>F</given-names></string-name>, <string-name><surname>Fiorina</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Catena</surname> <given-names>E</given-names></string-name>, <string-name><surname>Corsico</surname> <given-names>A</given-names></string-name>, <string-name><surname>Colombo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mirani</surname> <given-names>M</given-names></string-name>, <string-name><surname>De Riva</surname> <given-names>C</given-names></string-name>, <string-name><surname>Oleandri</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Abdi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bonventre</surname> <given-names>JV</given-names></string-name>, <string-name><surname>Rusconi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Folli</surname> <given-names>F</given-names></string-name>, <string-name><surname>Di Sabatino</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zuccotti</surname> <given-names>G</given-names></string-name>, <string-name><surname>Galli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fiorina</surname> <given-names>P.</given-names></string-name> <article-title>Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study</article-title>. <source>DIABETES CARE</source> <year>2020</year>; <volume>43</volume>(<issue>12</issue>):<fpage>2999</fpage>&#x2013;<lpage>3006</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Hariyanto</surname> <given-names>TI</given-names></string-name>, <string-name><surname>Kurniawan</surname> <given-names>A.</given-names></string-name> <article-title>Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection</article-title>. <source>Obesity Medicine</source> <year>2020</year>; <volume>19</volume>:<fpage>100290</fpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Lukito</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Pranata</surname> <given-names>R</given-names></string-name>, <string-name><surname>Henrina</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Lawrensia</surname> <given-names>S</given-names></string-name>, <string-name><surname>Suastika</surname> <given-names>K.</given-names></string-name> <article-title>The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis</article-title>. <source>Diabetes &#x0026; Metabolic Syndrome: Clinical Research &#x0026; Reviews</source> <year>2020</year>; <volume>14</volume>(<issue>6</issue>):<fpage>2177</fpage>&#x2013;<lpage>2183</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Kow</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Hasan</surname> <given-names>SS</given-names></string-name>. <article-title>Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis</article-title>. <source>J MED VIROL</source> <year>2021</year>; <volume>93</volume>(<issue>2</issue>):<fpage>695</fpage>&#x2013;<lpage>697</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Hoyte</surname> <given-names>C.</given-names></string-name> <article-title>Review of Biguanide (Metformin) Toxicity</article-title>. <source>J INTENSIVE CARE MED</source> <year>2018</year>; <volume>34</volume>(<issue>11- 12</issue>):<fpage>863</fpage>&#x2013;<lpage>876</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Leng</surname> <given-names>Q.</given-names></string-name> <article-title>Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury</article-title>. <source>FRONT IMMUNOL</source> <year>2020</year>; <volume>11</volume>:<fpage>2056</fpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Pan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Han</surname> <given-names>R</given-names></string-name>, <string-name><surname>He</surname> <given-names>Y.</given-names></string-name> <article-title>Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?</article-title> <source>Zhonghua wei zhong bing ji jiu yi xue</source> <year>2020</year>; <volume>32</volume>(<issue>9</issue>):<fpage>1131</fpage>&#x2013;<lpage>1134</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Malhotra</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hepokoski</surname> <given-names>M</given-names></string-name>, <string-name><surname>McCowen</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Y-J Shyy</surname> <given-names>J.</given-names></string-name> <article-title>ACE2, Metformin, and COVID-19</article-title>. <source>iScience</source> <year>2020</year>; <volume>23</volume>(<issue>9</issue>):<fpage>101425</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Sharma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ray</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sadasivam</surname> <given-names>B.</given-names></string-name> <article-title>Metformin in COVID-19: A possible role beyond diabetes</article-title>. <source>DIABETES RES CLIN PR</source> <year>2020</year>; <volume>164</volume>:<fpage>108183</fpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Yan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Valdes</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Vijay</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Du</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>T</given-names></string-name>, <string-name><surname>Aithal</surname> <given-names>GP</given-names></string-name>. <article-title>Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study</article-title>. <source>CLIN PHARMACOL THER</source> <year>2020</year>; <volume>108</volume>(<issue>6</issue>):<fpage>1185</fpage>&#x2013;<lpage>1194</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Scheen</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Marre</surname> <given-names>M</given-names></string-name>, <string-name><surname>Thivolet</surname> <given-names>C.</given-names></string-name> <article-title>Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports</article-title>. <source>DIABETES METAB</source> <year>2020</year>; <volume>46</volume>(<issue>4</issue>):<fpage>265</fpage>&#x2013;<lpage>271</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Bardaweel</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Hajjo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sabbah</surname> <given-names>DA</given-names></string-name>. <article-title>Sitagliptin: a potential drug for the treatment of COVID-19?</article-title> <source>Acta pharmaceutica (Zagreb, Croatia)</source> <year>2021</year>; <volume>71</volume>(<issue>2</issue>):<fpage>175</fpage>&#x2013;<lpage>184</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Schlicht</surname> <given-names>K</given-names></string-name>, <string-name><surname>Rohmann</surname> <given-names>N</given-names></string-name>, <string-name><surname>Geisler</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hollstein</surname> <given-names>T</given-names></string-name>, <string-name><surname>Knappe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hartmann</surname> <given-names>K</given-names></string-name>, <string-name><surname>Schwarz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tran</surname> <given-names>F</given-names></string-name>, <string-name><surname>Schunk</surname> <given-names>D</given-names></string-name>, <string-name><surname>Junker</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bahmer</surname> <given-names>T</given-names></string-name>, <string-name><surname>Rosenstiel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schulte</surname> <given-names>D</given-names></string-name>, <string-name><surname>T&#x00FC;rk</surname> <given-names>K</given-names></string-name>, <string-name><surname>Franke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Schreiber</surname> <given-names>S</given-names></string-name>, <string-name><surname>Laudes</surname> <given-names>M.</given-names></string-name> <article-title>Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections</article-title>. <source>INT J OBESITY</source> <year>2020</year>; <volume>44</volume>(<issue>11</issue>):<fpage>2335</fpage>&#x2013;<lpage>2338</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Mozafari</surname> <given-names>N</given-names></string-name>, <string-name><surname>Azadi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mehdi-Alamdarlou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ashrafi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Azadi</surname> <given-names>A.</given-names></string-name> <article-title>Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin</article-title>. <source>MED HYPOTHESES</source> <year>2020</year>; <volume>143</volume>:<fpage>110111</fpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Singh Tomar</surname> <given-names>PP</given-names></string-name>, <string-name><surname>Arkin</surname> <given-names>IT</given-names></string-name>. <article-title>SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine</article-title>. <source>BIOCHEM BIOPH RES CO</source> <year>2020</year>; <volume>530</volume>(<issue>1</issue>):<fpage>10</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Cure</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cure</surname> <given-names>MC</given-names></string-name>. <article-title>Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis</article-title>. <source>Diabetes &#x0026; Metabolic Syndrome</source> <year>2020</year>; <volume>14</volume>(<issue>4</issue>):<fpage>405</fpage>&#x2013;<lpage>406</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Longo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Caruso</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maiorino</surname> <given-names>MI</given-names></string-name>, <string-name><surname>Bellastella</surname> <given-names>G</given-names></string-name>, <string-name><surname>Giugliano</surname> <given-names>D</given-names></string-name>, <string-name><surname>Esposito</surname> <given-names>K.</given-names></string-name> <article-title>Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies</article-title>. <source>CARDIOVASC DIABETOL</source> <year>2020</year>; <volume>19</volume>(<issue>1</issue>):<fpage>115</fpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Penlioglou</surname> <given-names>T</given-names></string-name>, <string-name><surname>Papachristou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Papanas</surname> <given-names>N.</given-names></string-name> <article-title>COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher&#x2019;s Stone?</article-title> <source>DIABETES THER</source> <year>2020</year>; <volume>11</volume>(<issue>6</issue>):<fpage>1195</fpage>&#x2013;<lpage>1197</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Erol</surname> <given-names>A.</given-names></string-name> <article-title>Role of oxidized LDL-induced &#x201C;trained macrophages&#x201D; in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis</article-title>. <source>Diabetes &#x0026; Metabolic Syndrome</source> <year>2020</year>; <volume>14</volume>(<issue>4</issue>):<fpage>713</fpage>&#x2013;<lpage>714</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname> <given-names>L</given-names></string-name>, <string-name><surname>She</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Qin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lei</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Song</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xiang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>L</given-names></string-name>, <string-name><surname>Xiang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>G</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>B</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ye</surname> <given-names>P</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>B</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H.</given-names></string-name> <article-title>Association of Blood Glucose Control and Outcomes in Patients with COVID- 19 and Pre-existing Type 2 Diabetes</article-title>. <source>CELL METAB</source> <year>2020</year>; <volume>31</volume>(<issue>6</issue>):<fpage>1068</fpage>&#x2013;<lpage>1077</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Iaccarino</surname> <given-names>G</given-names></string-name>, <string-name><surname>Grassi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Borghi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ferri</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salvetti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Volpe</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cicero</surname> <given-names>AFG</given-names></string-name>, <string-name><surname>Minuz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Muiesan</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Mulatero</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mul&#x00E8;</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pucci</surname> <given-names>G</given-names></string-name>, <string-name><surname>Savoia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sechi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Carugo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fallo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Giannattasio</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grassi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Letizia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Perlini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rizzoni</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sarzani</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tocci</surname> <given-names>G</given-names></string-name>, <string-name><surname>Veglio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Agabiti Rosei</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bevilacqua</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bisogni</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bombelli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bulfone</surname> <given-names>L</given-names></string-name>, <string-name><surname>Canichella</surname> <given-names>F</given-names></string-name>, <string-name><surname>Carpani</surname> <given-names>G</given-names></string-name>, <string-name><surname>Catanuso</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chiarini</surname> <given-names>G</given-names></string-name>, <string-name><surname>Chiumiento</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cianci</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cipollini</surname> <given-names>F</given-names></string-name>, <string-name><surname>Concistr&#x00E8;</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dalbeni</surname> <given-names>A</given-names></string-name>, <string-name><surname>De Blasi</surname> <given-names>RA</given-names></string-name>, <string-name><surname>De Ciuceis</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dell Oro</surname> <given-names>R</given-names></string-name>, <string-name><surname>Di Guardo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Di Lorenzo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Di Norcia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ervo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Eula</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fabbricatore</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fanelli</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fava</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grasso</surname> <given-names>E</given-names></string-name>, <string-name><surname>Grimaldi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Illario</surname> <given-names>M</given-names></string-name>, <string-name><surname>Invernizzi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Iraca</surname> <given-names>E</given-names></string-name>, <string-name><surname>Liegi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Malerba</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maloberti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mancusi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Molinari</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mussinelli</surname> <given-names>R</given-names></string-name>, <string-name><surname>Paini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pellimassi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Piazza</surname> <given-names>O</given-names></string-name>, <string-name><surname>Pontremoli</surname> <given-names>R</given-names></string-name>, <string-name><surname>Quarti Tevano</surname> <given-names>F</given-names></string-name>, <string-name><surname>Rabbia</surname> <given-names>F</given-names></string-name>, <string-name><surname>Rocco</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sabena</surname> <given-names>A</given-names></string-name>, <string-name><surname>Salinaro</surname> <given-names>F</given-names></string-name>, <string-name><surname>Schiavi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sgariglia</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Spannella</surname> <given-names>F</given-names></string-name>, <string-name><surname>Tedeschi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Viale</surname> <given-names>P.</given-names></string-name> <article-title>Age and Multimorbidity Predict Death Among COVID-19 Patients</article-title>. <source>HYPERTENSION</source> <year>2020</year>; <volume>76</volume>(<issue>2</issue>):<fpage>366</fpage>&#x2013;<lpage>372</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Higgins</surname> <given-names>JPT</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>SG</given-names></string-name>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>STAT MED</source> <year>2002</year>; <volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>&#x2013; <lpage>1558</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>